Life Science Companies to Watch 2025
Biolinq (San Diego CA, USA).
In September 2025, the company’s product Biolinq ShineTM was granted de novo classification by the FDA for the first fully autonomous needle free glucose sensor. A patch on the forearm provides real-time glucose feedback through a primary color-coded LED display, visible with or without a phone. Founded in 2012, in 2024 Biolinq raised $58m to fund its development program. Read more...
Salignostics (Jerusalem, Israel)
Salignostics has pioneered a revolutionary saliva-based diagnostic testing platform designed to be fast, safe, and user-friendly for both home use and point-of-care applications. Salistick™, the first and only CE-approved, saliva-based pregnancy test available on the market has found widespread recognition. Founded in 2016, in 2022 Salignostics raised $8m, bringin the total funds raised to $16m. Read more...
MI:RNA (Edinburgh, Scotland)
MI:RNA is a veterinary diagnostics company focused on early disease diagnosis through the combination of a revolutionary biomarker technology and artificial intelligence platform. Initially focused on companion animals, MI:RNA has now introduced a screening test for Johne’s disease in cattle. Founded in 2019 as a spin-out from Scotland’s Rural College (SRUC), MI:RNA raised $4m in 2024, bringin total investment to $5.62m. Read more...
SAVA (London, UK)
Sava Technologies has developed the world’s first multi-molecule biosensor capable of detecting biomarkers just under the skin in real-time, enabled by its proprietary microsensing technology. Its first product – a pain-free, affordable, and accurate Continuous Glucose Monitor (CGM) – showed up to 10 days of accurate, real-time glucose monitoring in 25 patients with diabetes. Founded in 2019 by two students from Imperial College, the company raised $8m in seed funding in 2024, followed by $16m in 2025. Read more...
Nutromics (Melbourne, Australia and San Diego CA, USA)
Nutromics technology uses Electrochemical Aptamer-Based (EAB) sensors in a microarray skin patch. The Company has developed the world’s first real-time, continuous data on two critical antibiotics - vancomycin and tobramycin - measured simultaneously on the same device in animal models. Founded in 2017 in Melbourne, AU, Nutromics has raised approximately A$60m, including A$7.5m in September 2025 to fund manufacturing facilities and on-going clinical trials. Read more...
Sensor100 has no ownership or other commercial interest in any of the above companies.
